Nutrigenomics-Based Personalized Supplements Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

Description

The Nutrigenomics-Based Personalized Supplements Market exceeded USD 1.82 billion in 2025 and is projected to grow at 14.5% CAGR to reach USD 7.16 billion by 2035. Testing, interpretation, and tailored formulations increasingly operate within recurring programs that connect biological information with convenient supplement delivery.

Market Scope
Start Year	2025
Forecast Year	2026-2035
Start Value	$1.82 Billion
Forecast Value	$7.16 Billion
CAGR	14.5%

Established supplement spending creates a consumer base already familiar with purchasing products for wellness routines. Personalized programs can build on those habits by turning test results into straightforward formulation and replenishment decisions. Lower sequencing costs improve the economics of that transition, allowing providers to obtain broader biological profiles without a proportionate increase in test inputs. Testing can consequently become the entry point for continuing formulation, coaching, and reassessment relationships. Artificial intelligence adds value by interpreting genomic, microbiome, metabolic, and behavioral information together. Recommendations can change as consumers provide new data, supporting programs that offer more than a static variant report. Operators need to connect data capture with formulation logic and an understandable subscriber experience to realize this opportunity. The commercial effect favors integrated platforms that combine accessible testing with continuing interpretation and fulfillment, while established wellness spending supports willingness to pay for a regimen that makes complex biological insights easier to use.

Based on type, personalized supplement formulations are projected to reach USD 3.91 billion by 2035. Tailored vitamins, minerals, probiotics, fatty acids, amino acids, and specialty nutraceuticals convert an initial assessment into recurring product demand. Providers can adjust the regimen around an individual's profile, giving formulation a continuing role after testing is complete. This differs commercially from selling a stand-alone kit because replenishment creates repeated contact with the customer. The category's relevance therefore depends on connecting assessment outputs with a usable delivery model. Formulation quality and convenient program operation help providers maintain that relationship. Operators with testing and interpretation capabilities can link biological inputs to the products subscribers receive, supporting a more continuous purchasing experience than isolated supplement or test transactions.

By personalization approach, DNA and genomic testing held a 52.0% share in 2025. Genetic information supplies a durable reference point for insights concerning nutrient metabolism, absorption, and predispositions. That baseline makes the approach an accessible route into tailored supplementation. Its relative position changes as providers add other biological and lifestyle inputs, rather than because genomic information becomes irrelevant. Programs can retain DNA results within a broader interpretation system while incorporating more dynamic signals. The commercial role of genetic testing is consequently connected to how providers use it after the initial assessment. An enduring baseline supports ongoing recommendations, while complementary data can improve responsiveness. Suppliers that integrate these inputs can develop a continuing consumer relationship without treating each subsequent formulation decision as a new genetic-testing purchase.

The North America nutrigenomics-based personalized supplements market held a 44.4% share in 2025. Familiarity with direct-to-consumer health products, established supplement purchasing, and a substantial group of platform developers support adoption. Practitioner participation adds another route to programs requiring professional interpretation. The United States combines home genetic-testing experience with functional medicine, integrative care, and digital-health providers, making it a setting for subscriptions that link home collection with online results and clinical involvement where appropriate. Canada benefits from access to these offerings and a developing preventive-nutrition practitioner base. Providers must still align product and privacy practices with local expectations. Regional demand therefore rests on consumer familiarity and service infrastructure together, with laboratory credibility, professional confidence, and accessible delivery helping convert interest into continuing participation.

Thorne HealthTech held a 5.5% market share in 2025. Supplement expertise, biological testing, interpretation, and practitioner relationships support its ability to connect assessment with recurring wellness purchasing. That breadth gives the company access to both consumer and professionally influenced programs. Its pending acquisition by PandG indicates strategic interest in premium platforms that combine scientific positioning with supplement delivery. The company's competitive role extends beyond selling individual products because testing and practitioner connections support a more integrated customer experience. Maintaining formulation quality and interpretation credibility remains important as buyers compare providers. Thorne's position reflects the value of bringing those capabilities together within a platform that translates biological inputs into products and ongoing engagement.

Some of the major players in this market are Metagenics, Viome Life Sciences, Genova Diagnostics, ZOE, Nutrigenomix, InsideTracker, GenePlanet, GX Sciences (Fagron Genomics US), MyDNA, Persona Nutrition, CircleDNA (Prenetics Global), SelfDecode, LifeDNA, Rootine, and Toolbox Genomics. Viome emphasizes functional biological analysis and made-to-order formulations, while Metagenics and Nutrigenomix address practitioner-led personalization. Genova supplies clinical testing inputs, and ZOE combines biological feedback with dietary insights. InsideTracker connects biomarkers and DNA-informed recommendations with performance and wellness goals. Other providers pursue direct testing, pharmacy partnerships, lifestyle integration, and subscription packs. Interpretation quality, trust, formulation capability, and channel access differentiate these approaches as testing becomes more accessible.

Product Code: 14919

Chapter 1. Methodology

1.1 Market Scope and Definition
1.2 Research Design
- 1.2.1 Research Approach
- 1.2.2 Data Collection Methods
1.3 Data Mining Sources
- 1.3.1 Global
- 1.3.2 Regional/Country
1.4 Base Estimates and Calculations
- 1.4.1 Base Year Calculation
- 1.4.2 Key Trends for Market Estimation
1.5 Primary Research and Validation
- 1.5.1 Primary Sources
1.6 Forecast Model
1.7 Research Assumptions and Limitations

Chapter 2. Executive Summary

2.1 Industry 360° Synopsis
2.2 Key Market Trends
- 2.2.1 Regional
- 2.2.2 Type
- 2.2.3 Personalization
- 2.2.4 Application
- 2.2.5 Distribution Channel
2.3 TAM Analysis, 2027–2035
2.4 CXO Perspectives: Strategic Imperatives
- 2.4.1 Executive Decision Points
- 2.4.2 Critical Success Factors
2.5 Future Outlook and Strategic Recommendations

Chapter 3. Industry Insights

3.1 Industry Ecosystem Analysis
- 3.1.1 Supplier Landscape
- 3.1.2 Profit Margin
- 3.1.3 Cost Structure
- 3.1.4 Value Addition at Each Stage
- 3.1.5 Factors Affecting the Value Chain
- 3.1.6 Disruptions
3.2 Industry Impact Forces
- 3.2.1 Growth Drivers
- 3.2.2 Industry Pitfalls and Challenges
- 3.2.3 Market Opportunities
3.3 Growth Potential Analysis
3.4 Pricing Analysis (Driven by Primary Research)
- 3.4.1 Historical Price Trend Analysis (Driven by Primary Research)
- 3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-Plus) (Driven by Primary Research)
3.5 Regulatory Landscape
- 3.5.1 North America
- 3.5.2 Europe
- 3.5.3 Asia Pacific
- 3.5.4 Latin America
- 3.5.5 Middle East and Africa
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Trade Data Analysis (Based on Paid Database)
- 3.8.1 Import/Export Volume & Value Trends (Based on Paid Database)
- 3.8.2 Key Trade Corridors & Tariff Impact (Based on Paid Database)
3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
- 3.9.1 AI-Driven Disruption of Existing Business Models
- 3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
- 3.9.3 Risks, Limitations & Regulatory Considerations

Chapter 4. Competitive Landscape, 2025

4.1 Introduction
4.2 Company Market Share Analysis
- 4.2.1 By Region
  - 4.2.1.1 North America
  - 4.2.1.2 Europe
  - 4.2.1.3 Asia Pacific
  - 4.2.1.4 Latin America
  - 4.2.1.5 Middle East & Africa
4.3 Company Matrix Analysis
4.4 Competitive Analysis of Major Market Players
4.5 Competitive Positioning Matrix
4.6 Key Developments
- 4.6.1 Mergers & Acquisitions
- 4.6.2 Partnerships & Collaborations
- 4.6.3 New Product Launches
- 4.6.4 Expansion Plans

Chapter 5. Nutrigenomics-Based Personalized Supplements Market Estimates & Forecast, By Offering Type (USD Million, 2022–2035)

5.1 Genetic Testing Kits & Reagents
- 5.1.1 Saliva-Based DTC Genetic Test Kits
- 5.1.2 Blood-Based Clinical Genetic Testing Kits
- 5.1.3 SNP Genotyping Arrays & Microarray Panels
- 5.1.4 Next-Generation Sequencing (NGS)-Based Kits
5.2 Bioinformatics & AI Interpretation Platforms
- 5.2.1 Cloud-Based Nutrigenomic Analysis Platforms
- 5.2.2 On-Premise Clinical Bioinformatics Solutions
- 5.2.3 API-Integrated & White-Label Platforms
5.3 Personalized Supplement Formulations
- 5.3.1 Precision Vitamins & Minerals
- 5.3.2 Personalized Probiotics & Prebiotics
- 5.3.3 Omega-3 & Essential Fatty Acid Formulations
- 5.3.4 Amino Acid & Protein Blends
- 5.3.5 Specialty Nutraceuticals & Adaptogens
- 5.3.6 Multi-Component Personalized Supplement Packs

Chapter 6. Nutrigenomics-Based Personalized Supplements Market Estimates & Forecast, By Personalization Approach (USD Million, 2022–2035)

6.1 DNA/Genomic Testing-Based Personalization
- 6.1.1 SNP Panel-Based
- 6.1.2 Whole Genome Sequencing (WGS)-Based
- 6.1.3 Targeted Gene Panel-Based
6.2 Microbiome-Based Personalization
- 6.2.1 16S rRNA Microbiome Profiling
- 6.2.2 Shotgun Metagenomics & RNA Metatranscriptomics Profiling
6.3 Multi-Omics Integration
- 6.3.1 Genomics + Microbiome Integration
- 6.3.2 Genomics + Metabolomics Integration
- 6.3.3 Full Multi-Omics Stack (Genomics + Microbiome + Metabolomics + Epigenomics)
6.4 Lifestyle & Phenotypic Data Integration
- 6.4.1 Biomarker + Genetic Data Integration
- 6.4.2 Wearable + Genetic Data Integration
- 6.4.3 Dietary Habit & Activity-Augmented Genomic Profiling

Chapter 7. Nutrigenomics-Based Personalized Supplements Market Estimates & Forecast, By Application (USD Million, 2022–2035)

7.1 Obesity & Weight Management
- 7.1.1 Metabolic Rate & Fat Storage Gene Variant Targeting
- 7.1.2 Appetite Regulation & Satiety Genomic Supplement Programs
7.2 Cardiovascular Health
- 7.2.1 Lipid Metabolism & APOE Variant-Targeted Supplements
- 7.2.2 MTHFR & Homocysteine Management Formulations
7.3 Diabetes & Metabolic Disorders
- 7.3.1 Insulin Sensitivity & Glucose Metabolism Gene-Targeted Supplements
- 7.3.2 Type 2 Diabetes Risk Reduction Genomic Programs
7.4 Sports Nutrition & Performance
- 7.4.1 Muscle Fiber Composition & Power/Endurance Gene Profiling
- 7.4.2 Recovery & Inflammation Gene-Targeted Supplement Stacks
7.5 Cognitive & Brain Health
- 7.5.1 COMT Polymorphism & Catecholamine Metabolism Supplements
- 7.5.2 BDNF Variant-Targeted Nootropic & Neuroprotective Formulations
7.6 Immune Health
- 7.6.1 Vitamin D Receptor (VDR) Variant-Targeted Immune Supplements
- 7.6.2 Inflammatory Gene Variant (TNF-α, IL-6) Targeted Formulations
7.7 General Wellness & Longevity
- 7.7.1 Anti-Aging Genomic Supplement Programs
- 7.7.2 Epigenetic Optimization & Methylation Support Formulations
7.8 Others

Chapter 8. Nutrigenomics-Based Personalized Supplements Market Estimates & Forecast, By Distribution Channel (USD Million, 2022–2035)

8.1 Direct-to-Consumer (DTC) Online / E-Commerce
- 8.1.1 Brand-Owned DTC Subscription Platforms
- 8.1.2 Third-Party E-Commerce Marketplaces
8.2 Healthcare Practitioner / Clinical Channel
- 8.2.1 Registered Dietitians & Clinical Nutritionists
- 8.2.2 Integrative Medicine & Functional Medicine Practitioners
- 8.2.3 Hospital & Clinical Nutrition Centers
8.3 Pharmacies & Health Retail Stores
- 8.3.1 Chain Pharmacy Networks
- 8.3.2 Specialty Health & Wellness Retailers
8.4 Others
- 8.4.1 Corporate Wellness & Employee Health Programs
- 8.4.2 Genomics Specialty Clinics & Testing Centers
- 8.4.3 Telehealth & Digital Health Platform-Integrated Distribution

Chapter 9. Nutrigenomics-Based Personalized Supplements Market Estimates & Forecast, By Region (USD Million, 2022–2035)

9.1 North America
- 9.1.1 U.S.
- 9.1.2 Canada
9.2 Europe
- 9.2.1 Germany
- 9.2.2 UK
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 South Korea
- 9.3.5 Australia
- 9.3.6 Rest of Asia Pacific
9.4 Latin America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Rest of Latin America
9.5 Middle East & Africa
- 9.5.1 Saudi Arabia
- 9.5.2 UAE
- 9.5.3 South Africa
- 9.5.4 Rest of Middle East & Africa

Chapter 10. Company Profiles (Driven by Primary Research)

10.1 Thorne HealthTech
10.2 Metagenics
10.3 Viome Life Sciences
10.4 Genova Diagnostics
10.5 ZOE
10.6 Nutrigenomix
10.7 InsideTracker
10.8 GenePlanet
10.9 GX Sciences (Fagron Genomics US)
10.10 MyDNA
10.11 Persona Nutrition
10.12 CircleDNA (Prenetics Global)
10.13 SelfDecode
10.14 LifeDNA
10.15 Rootine
10.16 Toolbox Genomics